Cloning and pharmacological characterization of a novel gene encoding human nucleoside transporter 1 (hNT1) from a human breast cancer cDNA library

Life Sciences

Volumn 84, Issue 1-2, 2009, Pages 45-51

  Umemoto, Takahiro ^a,b   Kobayashi, Yasuna ^a   Suzuki, Masako ^a,b   Sanada, Yutaka ^b   Yamamoto, Toshinori ^a  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Breast cancer; Drug transporter; Nucleoside transporter

Indexed keywords

COMPLEMENTARY DNA; FLUOROURACIL; NUCLEOSIDE DERIVATIVE; NUCLEOSIDE TRANSPORTER; PROTEIN HUMAN NUCLEOSIDE TRANSPORTER 1; SODIUM ION; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST DUCT; CONTROLLED STUDY; DNA LIBRARY; GENE EXPRESSION SYSTEM; GENE FUNCTION; GENE ISOLATION; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OOCYTE; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; XENOPUS LAEVIS;

AMINO ACID SEQUENCE; BASE SEQUENCE; BREAST NEOPLASMS; CLONING, MOLECULAR; FLUOROURACIL; GENE LIBRARY; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; NUCLEOSIDE TRANSPORT PROTEINS;

XENOPUS LAEVIS;

EID: 57649187260     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.10.015     Document Type: Article

References (44)

1. Baldwin S.A., Beal P.R., Yao S.Y., King A.E., Cass C.E., and Young J.D. The equilibrative nucleoside transporter family, SLC29. Pflügers Archiv European Journal of Pharmacology 447 (2004) 735-743
2. Bonadonna G., and Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Research 48 (1988) 2314-2324
3. Cass C.E., Young J.D., and Baldwin S.A. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochemistry and Cell Biology 76 (1998) 761-770
4. Clumeck N. Current use of anti-HIV drugs in AIDS. The Journal of Antimicrobial Chemotherapy 32 Suppl A (1993) 133-138
5. Colleoni M., Litman H.J., Castiglione-Gertsch M., Sauerbrei W., Gelber R.D., Bonetti M., et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. British Journal of Cancer 86 (2002) 1705-1714
6. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
7. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (1998) 930-942
8. Enomoto A., and Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clinical and Experimental Nephrology 9 (2005) 195-205
9. Eraly S.A., Monte J.C., and Nigam S.K. Novel slc22 transporter homologs in fly, worm, and human clarify the phylogeny of organic anion and cation transporters. Physiological Genomics 18 (2004) 12-24
10. Feinberg A.P., and Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Addendum. Analytical Biochemistry 137 (1984) 266-267
11. Fisher B., Brown A.M., Dimitrov N.V., Poisson R., Redmond C., Margolese R.G., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. Journal of Clinical Oncology 8 (1990) 1483-1496
12. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends in Pharmacological Sciences 25 (2004) 423-429
13. Gray J.H., Owen R.P., and Giacomini K.M. The concentrative nucleoside transporter family, SLC28. Pflügers Archiv 447 (2004) 728-734
14. Hagenbuch B., and Meier P.J. The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta 1609 (2003) 1-18
15. Hediger M.A., Romero M.F., Peng J.B., Rolfs A., Takanaga H., and Bruford E.A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Introduction. Pflügers Archiv European Journal of Pharmacology 447 (2004) 465-468
16. Ho G.T., Moodie F.M., and Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut 52 (2003) 759-766
17. Houssami N., Cuzick J., and Dixon J.M. The prevention, detection, and management of breast cancer. The Medical Journal of Australia 184 (2006) 230-234
18. Izuno H., Kobayashi Y., Sanada Y., Nihei D., Suzuki M., Kohyama N., et al. Rat organic solute carrier protein 1 (rOscp1) mediated the transport of organic solutes in Xenopus laevis oocytes: isolation and pharmacological characterization of rOscp1. Life Sciences 81 (2007) 1183-1192
19. Jeung H.C., Rha S.Y., Noh S.H., Min J.S., Kim B.S., and Chung H.C. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Cancer 91 (2001) 2016-2025
20. Kling K.M., Ostrzega N., and Schmit P. Breast conservation after induction chemotherapy for locally advanced breast cancer. The American Surgeon 63 (1997) 861-864
21. Kobayashi Y., Ohshiro N., Tsuchiya A., Kohyama N., Ohbayashi M., and Yamamoto T. Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metabolism and Disposition 32 (2004) 479-483
22. Kobayashi Y., Ohshiro N., Sakai R., Ohbayashi M., Kohyama N., and Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). The Journal of Pharmacy and Pharmacology 57 (2005) 573-578
23. Kobayashi Y., Shibusawa A., Saito H., Ohshiro N., Ohbayashi M., Kohyama N., et al. Isolation and functional characterization of a novel organic solute carrier protein, hOSCP1. The Journal of Biological Chemistry 280 (2005) 32332-32339
24. Kobayashi Y., Tsuchiya A., Hayashi T., Kohyama N., Ohbayashi M., and Yamamoto T. Isolation and characterization of polyspecific mouse organic solute carrier protein 1 (mOscp1). Drug Metabolism and Disposition 35 (2007) 1239-1245
25. Kusuhara H., Sekine T., Utsunomiya-Tate N., Tsuda M., Kojima R., Cha S.H., et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. The Journal of Biological Chemistry 274 (1999) 13675-13680
26. Leonessa F., and Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocrine-Related Cancer 10 (2003) 43-73
27. Li L., Meier P.J., and Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Molecular Pharmacology 58 (2000) 335-340
28. Lu R., Kanai N., Bao Y., and Schuster V.L. Cloning, in vitro expression and tissue distribution of a human prostaglandin transporter cDNA (hPGT). Journal of Clinical Investigation 98 (1996) 1142-1149
29. Mahagita C., Grassl S.M., Piyachaturawat P., and Ballatori N. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. American Journal of Physiology. Gastrointestinal and Liver Physiology 293 (2007) G271-G278
30. Miyazaki H., Sekine T., and Endou H. The multispecific organic anion transporter family: properties and pharmacological significance. Trends in Pharmacological Sciences 25 (2004) 654-662
31. Nozawa T., Suzuki M., Yabuuchi H., Irokawa M., Tsuji A., and Tamai I. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharmaceutical Research 22 (2005) 1634-1641
32. O'Regan M. Adenosine and the regulation of cerebral blood flow. Neurological Research 27 (2005) 175-181
33. Ribeiro J.A. What can adenosine neuromodulation do for neuroprotection? Current drug targets. CNS and Neurological Disorders 4 (2005) 325-329
34. Rumjanek V.M., Trindade G.S., Wagner-Souza K., de-Oliveira M.C., Marques-Santos L.F., Maia R.C., et al. Multidrug Resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. Anais da Academia Brasileira de Ciências 73 (2001) 57-69
35. Sapunar F., and Smith I.E. Neoadjuvant chemotherapy for breast cancer. Annals of Medicine 32 (2000) 43-50
36. Sawynok J. Adenosine receptor activation and nociception. European Journal of Pharmacology 347 (1998) 1-11
37. Sekine T., Cha S.H., and Endou H. The multispecific organic anion transporter (OAT) family. Pflügers Archiv European Journal of Pharmacology 440 (2000) 337-350
38. Sekine T., Miyazaki H., and Endou H. Molecular physiology of renal organic anion transporters. American Journal of Physiology Renal Physiology 290 (2006) F251-F261
39. Shryock J.C., and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. The American Journal of Cardiology 79 (1997) 2-10
40. Taylor K.M., Morgan H.E., Smart K., Zahari N.M., Pumford S., Ellis I.O., et al. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Molecular Medicine 13 (2007) 396-406
41. Vallon V., Muhlbauer B., and Osswald H. Adenosine and kidney function. Physiological Reviews 86 (2006) 901-940
42. Vivet-Boudou V., Didierjean J., Isel C., and Marquet R. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cellular and Molecular Life Sciences 63 (2006) 163-186
43. Willems L., Ashton K.J., and Headrick J.P. Adenosine-mediated cardioprotection in the aging myocardium. Cardiovascular Research 66 (2005) 245-255
44. Wright S.H. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicology and Applied Pharmacology 204 (2005) 309-319